The FDA rejects Vivus' (VVUS) obesity drug Qnexa, but shares of Vivus are +21.7% premarket as...

|By:, SA News Editor

The FDA rejects Vivus' (VVUS) obesity drug Qnexa, but shares of Vivus are +21.7% premarket as investors seemingly accept the company's confidence in the "efficacy and safety" of the drug. Vivus says it will have the info requested by the FDA ready for submission in around six weeks. (see also: I, II)